P.T.U Courses:
Admissions Open for B.Sc /M.Sc/PGD in Bioinformatics & Biotechnology.
For Further Details Please Contact:
Phone No: 0120-4320801\802
Mob: 09810535368, 09818473366
E-mail: info@bii.in,Visit us: www.bii.in
Blog of BII an Institute having thousands of program participants from more than 40 countries. BII is the training leader in emerging life science and pharma domains.The Blog Members are encouraged to share news, views, jobs, comments, with others. All the members (students, alumni, non students) are encouraged to Post and comment to the Blog. Blog focus is on Bioinformatics, Biotechnology, Pharma Regulatory Affairs, Clinical Trials, Drug Design and Discovery, IPR, GMP
P.T.U Courses:
Admissions Open for B.Sc /M.Sc/PGD in Bioinformatics & Biotechnology.
For Further Details Please Contact:
Phone No: 0120-4320801\802
Mob: 09810535368, 09818473366
E-mail: info@bii.in,Visit us: www.bii.in
Genocea Biosciences Agreement with U.S. Military to Develop Malaria vaccine
Cambridge: Genocea Biosciences, a leading vaccine discovery and development company, announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC). NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria. Genocea and NMRC will leverage their expertise to identify novel malaria vaccine candidate antigens and move promising antigens through preclinical development. Genocea will apply its technology to the rapid.
Identification of novel T-cell antigens from a proteomic screen of the P.falciparum organism, and NMRC will share material as well as their extensive experience developing subunit malaria vaccines. This work is funded by a $2.7 million award that was granted to Genocea from the U.S. Army Medical Research and Material Command (USAMRMC) for rapid T-cell screens of a P.falciparum proteomic library
New England Launches New Line of Proteomics Services
New England Peptide (NEP) introduced NEPTuneTM, a new Propriety line of custom proteomics reagents to help its customers to quickly and inexpensively maximize biomarker assay development and produce consistent result.
“Proteomics is an exciting research field that is poised to deliver the next generation of life- changing diagnosis tools and drug therapies diagnostics tools and drug therapies,” said Dave Robinson, NEP’s Executive Officer. “We have great interest in proteomic research and are pleased to be the only company providing this high quality, proprietary line of services to our customers. It marks a revolutionary step forward for NEP and the field of proteomics as a whole.” Proteomics is the large scale study of the set of proteins specified by genes within an organism with the aim to understand how biological systems operate on a fundamental level. Proteomics based (human) diagnostics and resultant therapies have the potential to allow physician treat disease states in a more specific and targeted approach, which will help deliver on the promise of personalized medicine and tailored therapies that have been discussed in the health care industry in recent years.
The NEPTuneTM line comprises a suite of four distinct solutions that align with the various needs of proteomics researcher and clinician, ranging from biomarker discovery through clinical assay production:
Robinson noted that NEP has been a leader in proteomics research for years has assembled a team – led by Chemical Development Vice President Robert Hammer, PhD and Proteomics Product Manager John Antogoni with consultation from NEP’s industry-leading scientific advisory board – that delivers the industry’s only single source of peptides optimized for quantitative proteomics.
NEPTuneTM is the latest in a line of proprietary product and process innovations developed by NEP’s in-house team. Last December, NEP launched PepScale TM, a proprietary peptide synthesis instrument, that better anables peptide scale-up and process development projects for its customers. In September, NEP rolled out PepCROTM, the first peptide –focused contract research service for drug, vaccine and diagnostic discovery projects. Last July, NEP unveiled FlashPureTM, the peptide industry’s first flash purification system.
Gentel Launches Detection Kit for Ultra-sensitive Chromogenic Detection of Protein
Microarrays
Gentel Biosciences, announced the availability of the APiX ViewTM Detection Kits for ultra- sensitive chromogenic detection of protein bmicroarrays, including reverse phase protein such as SomaPlexTM arrays from Protein Biotechnologies.
APiX chromogenic technology allows for the detection of any biotinylated molecule, generating light grey-to-black spots that are visible to the naked eye and can be scanned with the Gentel Proteomics Multi-System. APiX is also compatible with a variety of secondary antibodies such as anti-mouse anti-rabit. APiX uses a proprietary gold-catalyzed silver deposition and typically achieves measurably improved sensitivity compared to fluorescence
detection.
Phillip Schwartz, President and CEO of Protein biotechnologies recognized the potential of the Gentel reagent and systen for use with Protein Biotechnologies SomaPlexTM tumor lysate arrays. "Our customers are looking for a simple, sensitive, and affordable detection methods for use with SomaPlexTM arrays. The Gentel Prteomics Multisystem meets this need," stated Schwartz. "We are excited about how Gentel's easy-to-use kits and affordable
system can help make arrays accessible to whole a new group of users."
Tumor lysates arrays are a type of reverse phase protein microarray that contains a collection of up to several hundred tumor samples on slide. Antibodies or other probes are applied to the array to detect the abundance of specific protein biomarkers and rapidly measure expression across a large population of tumor samples. Array results are then compared to demographic and relevant clinical disease-specific data on the tumor collection to draw a conclusion. APiX bView detection reagents are compatible with the Gentel Proteomics Multi-System, which provides "scan-to-analysis" functionality for multiplex immunoassays, tumor lysates and antigen arrays as well as Western Blot, ELISA and tissue imaging.